Home/ARScience Biotherapeutics/Carlos Banando

CB

Carlos Banando

CEO

ARScience Biotherapeutics

Therapeutic Areas

Oncology Autoimmune Diseases

ARScience Biotherapeutics Pipeline

Drug	Indication	Phase
COYA 301 (Low-dose IL-2)	Autoimmune/Inflammatory (via Treg expansion)	Phase 1

Leadership Team at ARScience Biotherapeutics

Claudia Zylberberg

Chair and Co-founder

Jorge Zylberberg

View full ARScience Biotherapeutics profile